Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LUND, Sweden, Nov. 5, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Active Biotech AB (publ) has issued a notice to an Extraordinary General Meeting, which is to take place at 5 p.m. on Monday,...
-
LUND, Sweden, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Laquinimod · Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Styrelsen för Active Biotech AB (publ) har...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The Board of Directors of Active Biotech AB...
-
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, SINGAPORE, SYDAFRIKA ELLER NYA ZEELAND ELLER I NÅGON ANNAN...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod · Teva har presenterat nya kliniska...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod · Teva presented new clinical safety...
-
Studierna ARPEGGIO och LEGATO-HD ska ytterligare undersöka laquinimods effekt i neurodegenerativa sjukdomar Lund, Sverige och Jerusalem, Israel den 4 november, 2014 - Active Biotech (NASDAQ OMX...
-
ARPEGGIO and LEGATO-HD trials will further evaluate the effect of laquinimod in neurodegenerative diseases Jerusalem & Lund, Sweden - November 4, 2014 - Teva Pharmaceutical Industries Ltd....